Table 5 RYGB versus adjustable gastric banding outcomes comparison.

From: Comparison of bariatric surgery and community weight management for idiopathic intracranial hypertension in a multicenter retrospective cohort study

Outcome

Follow-up duration

RYGB

Adjustable gastric banding

Risk difference

Risk ratio

95% confidence interval

P-value

Papilledema

3 months

5.10%

5.10%

0

1

0.426–2.349

0.999

6 months

5.10%

5.10%

0

1

0.426–2.349

0.999

12 months

5.10%

5.10%

0

1

0.426–2.349

0.999

24 months

5.10%

6.12%

− 1.02%

0.833

0.369–1.884

0.6607

Increased ICP

3 months

5.10%

0

5.10%

N/A

N/A

0.0014

6 months

5.10%

0

5.10%

N/A

N/A

0.0014

12 months

5.10%

5.10%

0

1

0.426–2.349

0.999

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

Headache

3 months

31.12%

30.10%

1.02%

1.034

0.767–1.393

0.8265

6 months

41.84%

39.80%

2.04%

1.051

0.828–1.334

0.681

12 months

44.39%

44.39%

0.00%

1

0.801–1.248

0.999

24 months

50.51%

50.51%

0.00%

1

0.822–1.217

0.999

Optic atrophy

3 months

5.10%

5.10%

0

1

0.426–2.349

0.999

6 months

5.10%

5.10%

0

1

0.426–2.349

0.999

12 months

5.10%

5.10%

0

1

0.426–2.349

0.999

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

Blindness

3 months

5.10%

5.10%

0

1

0.426–2.349

0.999

6 months

5.10%

5.10%

0

1

0.426–2.349

0.999

12 months

5.10%

5.10%

0

1

0.426–2.349

0.999

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

Pulsatile tinnitus

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

5.10%

0

5.10%

N/A

N/A

0.0014

24 months

5.10%

0

5.10%

N/A

N/A

0.0014

Abducent nerve palsy

3 months

0

5.10%

− 5.10%

N/A

N/A

0.0014

6 months

0

5.10%

− 5.10%

N/A

N/A

0.0014

12 months

0

5.10%

− 5.10%

N/A

N/A

0.0014

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

Diplopia

3 months

5.10%

5.10%

0

1

0.426–2.349

0.999

6 months

5.10%

5.10%

0

1

0.426–2.349

0.999

12 months

5.10%

5.10%

0

1

0.426–2.349

0.999

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

Refractory IIH

3 months

30.61%

30.10%

0.51%

1.017

0.753–1.373

0.912

6 months

40.82%

39.29%

1.53%

1.039

0.815–1.324

0.7571

12 months

42.86%

42.86%

0

1

0.796–1.257

0.999

24 months

48.47%

48.98%

− 0.51%

0.99

0.808–1.212

0.9195

Visual discomfort and visual field defects

3 months

0

5.10%

− 5.10%

N/A

N/A

0.0014

6 months

5.10%

5.10%

0

1

0.426–2.349

0.999

12 months

5.10%

5.10%

0

1

0.426–2.349

0.999

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

CSF leak

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

0

0

N/A

N/A

N/A

N/A

Therapeutic spinal puncture rate

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

5.10%

− 5.10%

N/A

N/A

0.0014

12 months

0

5.10%

− 5.10%

N/A

N/A

0.0014

24 months

5.10%

5.10%

0

1

0.426–2.349

0.999

CSF shunting rate

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

0

0

N/A

N/A

N/A

N/A

ONSF rate

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

0

0

N/A

N/A

N/A

N/A

Acetazolamide use

3 months

15.31%

9.69%

5.61%

1.579

0.921–2.708

0.093

6 months

16.84%

13.27%

3.57%

1.269

0.79–2.04

0.3228

12 months

19.90%

17.35%

2.55%

1.147

0.757–1.737

0.5165

24 months

22.96%

20.92%

2.04%

1.098

0.755–1.595

0.6254

Back to article page